Bionano Genomics (BNGO) Payables (2017 - 2026)

Bionano Genomics' Payables history runs 10 years deep, the most recent figure standing at $15.2 million for Q1 2026.

• In Q1 2026, Payables fell 22.39% year-over-year to $15.2 million; the TTM figure through Mar 2026 stood at $15.2 million (down 22.39% YoY), while the FY2025 annual figure was $15.6 million, down 43.02% from the prior year.
• Payables came in at $15.2 million for Q1 2026 at Bionano Genomics, down from $15.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $80.2 million in Q4 2023 to a low of $6.6 million in Q1 2022.
• A 5-year average of $21.3 million and a median of $15.8 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables surged 539.76% in 2023 and tumbled 65.92% in 2024, its largest moves.
• Bionano Genomics' Payables stood at $12.5 million in 2022, then soared by 539.76% to $80.2 million in 2023, then sank by 65.92% to $27.3 million in 2024, then tumbled by 43.02% to $15.6 million in 2025, then slipped by 2.28% to $15.2 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $15.2 million, $15.6 million, and $15.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison